Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Name||fallopian tube serous adenocarcinoma|
|Definition||A fallopian tube adenocarcinoma that derives_from epithelial cells originating in glandular tissue forming serous lesions.|
|Path||disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer fallopian tube cancer fallopian tube carcinoma fallopian tube adenocarcinoma fallopian tube serous adenocarcinoma|
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02345265||Phase II||Cediranib + Olaparib||Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Active, not recruiting|
|NCT02354586||Phase II||Niraparib||A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens||Active, not recruiting|
|NCT02446600||Phase III||Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin||Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Active, not recruiting|
|NCT02898207||Phase I||Olaparib + Onalespib||Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer||Active, not recruiting|
|NCT03206645||Phase I||Carboplatin + Paclitaxel + PTC596||PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy||Recruiting|